Results 161 to 170 of about 82,211 (293)

Magnitude and Predictors of Leukopenia and Thrombocytopenia in Adults With HIV/AIDS Attending Mizan Tepi University Teaching Hospital, Southwest Ethiopia. [PDF]

Biomed Res Int
Kebede SS, Zeleke D, Belay T, Atilabachew E, Bambo GM.   +4 more
europepmc   +1 more source

Fruquintinib Plus TAS‐102 With or Without SBRT as Third‐ Or Later‐Line Therapy for Metastatic Colorectal Cancer: Preliminary Results From a Prospective Phase II Trial

Cancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Both fruquintinib and TAS‐102 monotherapies are guideline‐recommended for third‐line treatment of metastatic colorectal cancer (mCRC). This study aimed to analyze the preliminary outcomes of fruquintinib combined with TAS‐102, with or without stereotactic body radiation therapy (SBRT), as a third‐ or later‐line therapy for mCRC.
Yi Wang, Jianfen Xu, Linchun Liang, Yunjie Chen, Leizheng Fei, Jing Hu, Jianjiong Li, Yi Lu, Feng Ren, Ke Chen, Yanping Shen, Qingsong Tao, Zhi Fang, Kaitai Liu, Hua Ye, Jing Zhang, Yunbao Xu, Haoxun Mao, Chen Zhang, Chuangzhou Rao   +19 more
wiley   +1 more source

Efficacy of mizoribine in renal transplant recipients on calcineurin inhibitor-based immunosuppression: a network meta-analysis. [PDF]

Front Med (Lausanne)
Luo B, Yang B, Zhong C, Luo H.
europepmc   +1 more source

G‐CSF for Mobilizing CD34+ Cells in Individuals With SCD: A Word of Caution

American Journal of Hematology, Volume 101, Issue 6, Page 1178-1181, June 2026.
Akshay Sharma, Allistair Abraham, Monica Bhatia, María Cancio, Sonali Chaudhury, Selim Corbacioglu, Gregory M. T. Guilcher, Ashish O. Gupta, Rabi Hanna, Matthew M. Heeney, Tami John, Lakshmanan Krishnamurti, James L. LaBelle, Hemalatha G. Rangarajan, Shalini Shenoy, Elizabeth Stenger, Crawford Strunk, Courtney D. Fitzhugh   +17 more
wiley   +1 more source

Integration Analysis of Bayesian and Machine Learning for Heterogeneity, Biomarkers, and Optimal Combination Regimens of Pucotenlimab in Solid Tumors

Cancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT The efficacy of PD‐1 inhibitor pucotenlimab (HX008) in solid tumors exhibits heterogeneity. This study integrated data from 6 clinical trials (covering gastric/gastroesophageal junction cancer, triple‐negative breast cancer, melanoma, and dMMR/MSI‐H solid tumors) using Bayesian meta‐analysis, machine learning (optimal XGBoost AUC = 0.86), and ...
Yingge He, Changqing Gao, Shiyan Zhang, Yonghui Hao, Shuning He, Ke Peng, Liqi Li   +6 more
wiley   +1 more source

Applying the Lasso Model to Identify Risk Factors for Piperacillin-Tazobactam-Induced Leukopenia. [PDF]

Drug Des Devel Ther
Liu J, Yuan X, Liu X, Liu L, Wen L, Zheng F.   +5 more
europepmc   +1 more source

Cyclophosphamide and whole organ transplantation in human beings. [PDF]

, 1971
Booth, AS, Corman, JL, Groth, CG, Halgrimson, CG, Launois, B, Martineau, G, Penn, I, Porter, KA, Putnam, CW, Schroter, GT, Starzl, TE   +10 more
core  

Efficacy of Hepatic Artery Infusion Chemotherapy Combined With Regorafenib and Sintilimab Versus Regorafenib Alone in MSS/pMMR Colorectal Cancer Liver Metastases After Second‐Line Treatment Failure

Cancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Background Microsatellite stable/proficient mismatch repair (MSS/pMMR) colorectal cancer liver metastases (CRCLM) have limited treatment options after failure of second‐line systemic therapies. Hepatic artery infusion chemotherapy (HAIC) combined with targeted therapy and immunotherapy may offer improved outcomes.
Ran You, Qingyu Xu, Lixing Wang, Bin Leng, Chendong Wang, Zeyu Yu, Ya Lu, Lingfeng Diao, Yi Lu, Guowen Yin   +9 more
wiley   +1 more source

Exploring innovative G-CSF schedules in AML cytarabine-based consolidation through a digital twin study of white blood cell recovery. [PDF]

PLoS One
Reimann AM, Schalk E, Mougiakakos D, Fischer T, Sager S.   +4 more
europepmc   +1 more source

Acute Intermittent Porphyria Triggered by COVID‐19 Mimicking Guillain–Barré Syndrome: A Diagnostic Challenge

Clinical Case Reports, Volume 14, Issue 5, May 2026.
ABSTRACT Acute intermittent porphyria (AIP) is a rare heme biosynthesis disorder in which the accumulation of neurotoxic porphyrin precursors precipitates neurovisceral attacks. Intercurrent infections, including coronavirus disease 2019 (COVID‐19), may trigger or exacerbate AIP and complicate diagnosis, as clinical manifestations can resemble those of
Payman Sadeghi, Masood Ghahvechi Akbari, Seyed Abbas Hassani, Hosein Alimadadi, Morteza Heidari, Vahid Ziaee   +5 more
wiley   +1 more source